Serum beta 2 microglobulin in adult myeloid acute leukemias.
Serum beta 2 microglobulin levels, measured by radioimmunoassay (Phadebas test), were found increased in acute myeloid leukemias at diagnosis. Serum beta 2 microglobulin levels were significantly higher in patients with monocytic leukemias (13 patients, M4-M5 FAB classification) than in those with other cytological types (18 patients). Beta 2 microglobulin levels at diagnosis were correlated with serum lysozyme levels, but they were not correlated with blood blast counts, serum LDH and ferritin levels. 195 serum beta 2 microglobulin measurements were made serially in 30 patients with acute myeloid leukemias in first remission. Compared to values at diagnosis, beta 2 microglobulin levels in remission were significantly decreased. Out of 30 patients in remission 12 had increased serum beta 2 microglobulin levels (greater than 3 mg/l). Serial measurements were not predictive for relapses.
D000293:Adolescent; D000328:Adult; D003404:Creatinine / Q000097:blood; D005260:Female; D006801:Humans; D007668:Kidney / Q000503:physiopathology; D015470:Leukemia, Myeloid, Acute / Q000097:blood* / Q000175:diagnosis; D008297:Male; D009113:Muramidase / Q000378:metabolism; D011863:Radioimmunoassay; D001613:beta 2-Microglobulin / Q000032:analysis*
D001613:beta 2-Microglobulin; D003404:Creatinine; D009113:Muramidase